BRAF and neoplasm: Type I RAF inhibitors are ineffective in targeting the encoded RAF kinase dimers17 and may cause paradoxical upregulation of MAPK pathway signaling, in BRAF wild-type tumors or tumors harboring BRAF fusions, promoting accelerated tumor growth18,19.